Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
Dry Eye Disease (DED)
Interventions
DRUG

011516X (New Artificial Tear Formulation)

Topical eye drops

DRUG

Systane Ultra Multidose

Topical eye drops

DRUG

REFRESH PLUS®

Topical eye drops

Trial Locations (26)

14618

Rochester Ophthalmological Group, PC, Rochester

27262

Wake Forest Health Network Ophthalmology - Oak Hollow, High Point

30260

Clayton Eye Clinical Research, LLC, Morrow

30342

Georgia Eye Partners, Atlanta

32256

Bowden Eye & Associates, Jacksonville

33060

Clinical Research Center of Florida, Pompano Beach

33135

South Florida Research Center, Inc., Miami

33176

Vista Health Research, LLC, Miami

34429

Nature Coast Clinical Research, Crystal River

37205

Advancing Vision Research, Nashville

38119

Total Eye Care, PA, Memphis

40220

Senior Health Services, Louisville

45236

Eye Care Associates of Greater Cincinnati, Inc. dba Apex Eye, Cincinnati

63304

Ophthalmology Associates, Saint Charles

64154

Moyes Eye Center, Kansas City

66762

Kannarr Eye Care, LLC, Pittsburg

67114

Alliance for Multispecialty Research, LLC, Newton

78572

DCT-Shah Research, LLC dba Discovery Clinical Trials, Mission

89431

Eye Care Associates of Nevada, Sparks

90505

Wolstan & Goldberg Eye Associates, Torrance

91204

Global Research Management, Glendale

91702

Milton M. Hom, OD, FAAO, Azusa

91954

North Bay Eye Associates, Inc., Petaluma

92123

Eric M. White OD Inc, San Diego

92663

Eye Research Foundation, Newport Beach

02888

West Bay Eye Associates, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY